Small Cell Transformation in a Patient With RET Fusion-Positive Lung Adenocarcinoma on Pralsetinib

被引：6
|
作者：
Dimou, Anastasios [1 ]
Lo, Ying-Chun [2 ]
Merrell, Kenneth W. [3 ]
Halling, Kevin C. [2 ]
Mansfield, Aaron S. [1 ]
机构：
[1] Mayo Clin, Dept Oncol, Rochester, MN USA
[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[3] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA
来源：
JCO PRECISION ONCOLOGY | 2022年 / 6卷
关键词：
ACQUIRED-RESISTANCE; CANCER;
D O I：
10.1200/PO.22.00478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Small Cell Transformation in a Patient with RET Fusion Positive Lung Adenocarcinoma on Pralsetinib.
    Dimou, A.
    Lo, Y. -C.
    Halling, K.
    Mansfield, A. S.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S414 - S414
  • [2] Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer
    Nguyen, Ly
    Monestime, Shanada
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (07) : 527 - 533
  • [3] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
    Gao, Ming
    Zhang, Xia
    Yan, Huan
    Sun, Decong
    Yang, Xuejiao
    Yuan, Fang
    Ju, Yanfang
    Wang, Lijie
    Wang, Jinliang
    Zhao, Wei
    Zhang, Dong
    Li, Lin
    Xu, Xiaoyun
    Ma, Junxun
    Hu, Yi
    Zhang, Xiaotao
    [J]. SUPPORTIVE CARE IN CANCER, 2023, 31 (12)
  • [4] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
    Ming Gao
    Xia Zhang
    Huan Yan
    Decong Sun
    Xuejiao Yang
    Fang Yuan
    Yanfang Ju
    Lijie Wang
    Jinliang Wang
    Wei Zhao
    Dong Zhang
    Lin Li
    Xiaoyun Xu
    Junxun Ma
    Yi Hu
    Xiaotao Zhang
    [J]. Supportive Care in Cancer, 2023, 31
  • [5] Efficacy and safety of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer
    Zhou, Qing
    Zhao, Jun
    Chang, Jianhua
    Wang, Huijie
    Fan, Yun
    Wang, Ke
    Wu, Gang
    Nian, Weiqi
    Sun, Yuping
    Sun, Meili
    Wang, Xiangcai
    Shi, Huaqiu
    Zheng, Xiangqian
    Yao, Sheng
    Qin, Mengmeng
    Shen, Zhenwei
    Yang, Jason
    Wu, Yi-Long
    [J]. CANCER, 2023, 129 (20) : 3239 - 3251
  • [6] Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC
    Yahiya Y. Syed
    [J]. Drugs, 2022, 82 : 811 - 816
  • [7] Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC
    Syed, Yahiya Y.
    [J]. DRUGS, 2022, 82 (07) : 811 - 816
  • [8] Pralsetinib in patients with RET fusion-positive non-small cell lung cancer: A plain language summary of the ARROW study
    Griesinger, Frank
    Curigliano, Giuseppe
    Subbiah, Vivek
    Baik, Christina S.
    Tan, Daniel S. W.
    Lee, Dae H.
    Misch, Daniel
    Garralda, Elena
    Kim, Dong-Wan
    van der Wekken, Anthonie J.
    Gainor, Justin F.
    Paz-Ares, Luis
    Liu, Stephen, V
    Kalemkerian, Gregory P.
    Bowles, Daniel W.
    Mansfield, Aaron S.
    Lin, Jessica J.
    Smoljanovic, Vlatka
    Rahman, Ahmadur
    Zalutskaya, Alena
    Louie-Gao, Melinda
    Boral, Andy L.
    Mazieres, Julien
    [J]. FUTURE ONCOLOGY, 2024, 20 (06) : 297 - 306
  • [9] Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
    Faraat Ali
    Kumari Neha
    Garima Chauhan
    [J]. Archives of Pharmacal Research, 2022, 45 (5) : 309 - 327
  • [10] Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
    Ali, Faraat
    Neha, Kumari
    Chauhan, Garima
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 2022, 45 (05) : 309 - 327
12345